I. Putu Eka Widyadharma

I. Putu Eka Widyadharma

Auto-generated profile, based on publicly available information

I. Putu Eka Widyadharma

Department of Neurology, Faculty of Medicine, Universitas Udayana, Denpasar, Indonesia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EWElvan Wiyarta
Elvan Wiyarta
MFMarc Fisher
Marc Fisher
MKMohammad Kurniawan
Mohammad Kurniawan
RHRakhmad Hidayat
Rakhmad Hidayat
IGIskandar Purba Geraldi
Iskandar Purba Geraldi
JPJeyaraj Durai Pandian
Jeyaraj Durai Pandian
Stroke is a leading cause of disability and mortality worldwide, and it disproportionately affects low- and middle-income countries (LMICs), which account for 88% of stroke fatalities. Prehospital stroke care delays are a crucial obstacle to successful treatment in these settings, especially given the limited therapeutic window for thrombolytic treatments, which may greatly improve recovery chances when initiated early after stroke onset. These delays are caused by a lack of public understanding of stroke symptoms, sociodemographic and cultural variables, and insufficient healthcare infrastructure. This review discusses these issues in detail, emphasizing the disparities in stroke awareness and reaction times between locations and socioeconomic classes. Innovative options for reducing these delays include the deployment of mobile stroke units and community-based educational campaigns. This review also discusses how technology improvements and personalized educational initiatives might improve stroke awareness and response in LMICs. The primary goal is to give a thorough assessment of the challenges and potential remedies that might serve as the foundation for policy reforms and healthcare improvements in LMICs, eventually improving stroke care and lowering disease-related mortality and disability.

27 December 2020 in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Verified
Journal Article
Open access
PDF file
IWI. Putu Eka Widyadharma
I. Putu Eka Widyadharma
NSNi Nyoman Shinta Prasista Sari
Ni Nyoman Shinta Prasista Sari
KPKadek Enny Pradnyaswari
Kadek Enny Pradnyaswari
KYKadek Tresna Yuwana
Kadek Tresna Yuwana
IAI. Putu Gede Danika Adikarya
I. Putu Gede Danika Adikarya
DUDesak Ketut Indrasari Utami
Desak Ketut Indrasari Utami
Coronavirus disease 2019 (COVID-19) is a current global pandemic. The case number has increased since December 31, 2019. It has been reported that COVID-19 patients have been giving pain complaints, one of which is muscular pain. Other types of pain that have also been reported by COVID-19 patients are joint pain, stomach pain, and testicular pain. Neuropathic pain is the rarest case among others. COVID-19 mechanisms in the nerve and musculoskeletal damage are believed to be caused by the expression and distribution of angiotensin-converting enzyme 2 (ACE-2). Patients with pain, especially neuropathic pain, normally do not respond well to various therapies, and experience psychiatric disorders such as depression, which leads to a decrease in the patient’s quality of life. Important considerations for health professionals in terms of pain management during this pandemic include ensuring treatment continuity, painkillers, utilization of telemedicine, biopsychosocial management approach, and modifying therapy needs to reduce the risks of COVID-19 complications.

27 March 2019 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
IDI Gusti Agung Ayu Dharmawati
I Gusti Agung Ayu Dharmawati
TMTjokorda Gde Bagus Mahadewa
Tjokorda Gde Bagus Mahadewa
IWI Putu Eka Widyadharma
I Putu Eka Widyadharma
AIM: The purpose of this study was to determine the antibacterial activity of Lumbricus rubellus earthworms through inhibitory zone diameter to the growth of the bacterium Phorphyromonas gingivalis as the cause of periodontitis. METHODS: This was an experimental study with randomised posttest-only control group design. The study was conducted at the Microbiology Research Center laboratory at the Faculty of Dentistry, Airlangga University, Indonesia. The study was conducted in vitro, the sample size was calculated using the Federer formula as many as four agar plates containing bacteria Phorphyromonas gingivalis, with each plate given five different treatments: control (ethanol), Lumbricus rubellus earthworm extract (ECT) with concentrations of 50%, 25%, 12.5%, and 6.25% respectively. The data in the form of inhibition zone diameter (measured in millimetres) obtained were tested using One-Way ANOVA. RESULTS: The mean diameter of the inhibitory zone extract of Lumbricus rubellus earthworm on the growth of Phorphyromonas gingivalis bacteria in the treatment group had significant differences (p < 0.05). The mean inhibition zones between controls and the ECT treatment group (ECT 50%, ECT 25%, ECT 12.5%) were statistically different (p < 0.05), in contrast with ECT 6.25% (p > 0.05) which did not show significant difference with the control group (p > 0.05). CONCLUSION: Lumbricus rubellus earthworm extract with a concentration of 50% has the largest diameter of the inhibitory zone on the growth of the Phorphyromonas gingivalis bacteria. The 6.25% earthworm extract showed no antibacterial activity against the growth of Phorphyromonas gingivalis bacteria.

24 February 2024 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
BLBryan Gervais de Liyis
Bryan Gervais de Liyis
AAAnak Agung Istri Kosalya Arini
Anak Agung Istri Kosalya Arini
CKChrysanta Paramitha Karuniamaya
Chrysanta Paramitha Karuniamaya
NPNyoman Angga Krishna Pramana
Nyoman Angga Krishna Pramana
KTKumara Tini
Kumara Tini
ISIsmail Setyopranoto
Ismail Setyopranoto

15 November 2018 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
NGNyoman Golden
Nyoman Golden
TMTjokorda Gde Bagus Mahadewa
Tjokorda Gde Bagus Mahadewa
CACitra Aryanti
Citra Aryanti
IWI Putu Eka Widyadharma
I Putu Eka Widyadharma
BACKGROUND: The pathogenesis of inflammatory neuronal cell damage will continue after traumatic brain injury in which contributed to subsequent mortality. Serum S100B levels were shown to be an early predictor of mortality due to traumatic brain injury. AIM: This Meta-Analysis will analyse the mean and diagnostic strength of serum S100B levels between survived and died subjects with head injuries based on the various follow-up times of nine studies. METHODS: We conducted a meta-anelysis in accordance with PRISMA guidelines and adhering to Cochrane Handbook for Systematic Review of Interventions. Literature search was conducted on March 16, 2018 from Medline and Scopus in the past 10 years, using various keywords related to S100, brain injury, and outcome. Duplicate journals were sorted out via EndNote. Included articles were as follows: original data from the group, clinical trials, case series, patients undergoing serum S100B levels with both short- and long-term follow-up mortality. Data were collected for mortality, serum S100B levels, and its diagnostic strength. All data were analyzed using Review Manager 5.3 (Cochrane, Denmark). RESULTS: The results of the meta-analysis showed a significant difference in S100B levels between survived and died subjects with head injuries on overall follow-up timeline (0.91, 95.9% CI 0.7-1.12, I2 = 98%, p < 0.001), during treatment (1.43, 95% CI 0.97 to 1.89, I2 = 98%, p < 0.001), or 6 months (0.19; 95%CI 0.1-0.29, I2 = 76%, p < 0.001) with an average threshold value that varies according to the study method used. The mean diagnostic strength was also promising to predict early mortality (sensitivity of 77.18% and 92.33%, specificity of 78.35% and 50.6%, respectively). CONCLUSION: S100B serum levels in the future will be potential biomarkers, and it is expected that there will be standardised guidelines for their application.

1 October 2021 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
IWI.PUtu Eka Widyadharma
I.PUtu Eka Widyadharma
AKAngga Krishna
Angga Krishna
ASAndreas Soejitno
Andreas Soejitno
ALA.A.A. Putri Laksmidewi
A.A.A. Putri Laksmidewi
KTKumara Tini
Kumara Tini
III.A. Sri Indrayani
I.A. Sri Indrayani